GlassScriptPhysician profile
Cody Paul Collins
NPI 1215523741
$1,169.76
in general payments reported to CMS, 2019-2025
15 companies · $804 in 2025
The $804 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.04 · 2023: $15.54 · 2024: $333 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $554.86 | 2024-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.15 | 2024-2025 | Relistor |
| Vertex Pharmaceuticals Incorporated | $35.74 | 2024-2025 | |
| Abbvie INC. | $31.87 | 2025 | |
| Globus Medical, INC. | $31.12 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $29.59 | 2025 | |
| Foundation Fusion Solutions, LLC | $23.74 | 2025 | |
| Saluda Medical Americas, INC. | $20.36 | 2025 | Evoke |
| Biotronik Nro, INC. | $19.60 | 2025 | Prospera |
| Pfizer INC. | $18.55 | 2025 | |
| Lilly USA, LLC | $17.04 | 2022 | |
| Novo Nordisk INC | $15.54 | 2023 | Wegovy |
| Virtus Pharmaceuticals LLC | $15.34 | 2025 | Levorphanol Tartrate |
| Protega Pharmaceutials INC | $14.37 | 2024 | Roxybond |
| Spr Therapeutics, INC | $6.89 | 2024 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.